As one example, small molecule (SK-216) pharmacologic inhibition of the activity of the TGF-β1 target PAI-1 attenuates TGF-β1-induced fibroblast to myofibroblast transition and lung fibrosis (Omori et al., 2016). The gene discussed is TGFB1; the disease is pulmonary fibrosis.